Identifying fluoroquinolone-resistant bacteria in patients with weakened immune systems
Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic Patients
This study is looking at how to find certain resistant bacteria in patients with weakened immune systems, like those undergoing cancer treatment, so that doctors can create better ways to prevent infections and improve care for these patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11110470 on NIH RePORTER |
What this research studies
This research investigates how to screen for fluoroquinolone-resistant viridans group streptococci (VGS) in neutropenic patients, who are at high risk for severe infections. By identifying patients colonized with these resistant bacteria, the study aims to develop tailored infection prevention strategies that could replace standard fluoroquinolone prophylaxis. The approach includes determining the best screening methods and understanding the prevalence and risk factors associated with these infections. This could lead to more effective treatments and improved patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are neutropenic patients, particularly those with hematologic malignancies, who are at risk for infections.
Not a fit: Patients who are not neutropenic or those who do not have hematologic malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of severe infections in neutropenic patients by providing personalized infection prevention strategies.
How similar studies have performed: Previous research has shown promise in using screening methods for resistant bacteria in similar patient populations, indicating that this approach could be effective.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Satlin, Michael Joseph — Weill Medical Coll of Cornell Univ
- Study coordinator: Satlin, Michael Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.